A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Stopped Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
Conditions
- Ovarian Cancer
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Solid Tumor
Interventions
- DRUG: Rucaparib
- DRUG: Lucitanib
- DRUG: Sacituzumab govitecan
Sponsor
pharmaand GmbH
Collaborators